Back to results
US 11,766,481 B2Granted
Glycan modified short interfering RNA
AssigneesGanNA Bio, Inc., Children's Medical Center Corporation
InventorsRyan A. Flynn, Brian Goodman, Ciaran Lawlor, Namita Bisaria, Richard D. Cummings, Mohui Wei, Carolyn R. Bertozzi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to glycan-modified nucleic acids, including short interfering RNA molecules. The glycan-modified nucleic acids include an oligosaccharide moiety that is bond to the nucleic acid and that contains a multiple antennary complex type N-glycan. The disclosure also relates to pharmaceutical compositions containing such glycan-modified nucleic acids, and methods for making and using such glycan-modified nucleic acids.
Claims30
A pharmaceutical composition comprising:
- a) a glyconucleic acid or salt thereof, the glyconucleic acid comprising:
- i) a short interfering RNA (siRNA);
- and
- ii) at least one oligosaccharide moiety comprising at least 6 monosaccharides, covalently bound to the siRNA;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the at least one oligosaccharide moiety comprises a multiple antennary complex type N-glycan comprising at least one GlcNAc residue attached to the Manal-3 arm and at least one GlcNAc attached to the Manal-6 arm of a trimannose core.
4 more elements
Dependencies are inferred from the claim text.